Gastroparesis Drugs Market Growth Outlook Through 2024-2033

Gastroparesis drugs are medications used to manage and treat gastroparesis, a condition where the stomach’s ability to empty its contents is delayed, causing symptoms such as nausea, vomiting, and abdominal pain. These drugs typically include prokinetics to stimulate stomach motility, antiemetics to control nausea and vomiting, and medications to manage pain and other symptoms associated with the condition.

Sizing and Forecast
The gastroparesis drugs market size has grown strongly in recent years. It will grow from $5.09 billion in 2023 to $5.39 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to side effects of existing treatments, gastrointestinal motility research, clinical need, patient advocacy, and regulatory support.

The gastroparesis drugs market size is expected to see strong growth in the next few years. It will grow to $6.81 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to the increasing prevalence of diabetes, the aging population, rising awareness and diagnosis rates, increase in healthcare expenditure, and government and private funding. Major trends in the forecast period include advancements in gastroenterology, improved diagnostic techniques, technological innovations, research funding, and collaborative research efforts.

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Segmentation & Regional Insights
The gastroparesis drugs market covered in this report is segmented –

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs
2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes
3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types
4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration
5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

North America was the largest region in the gastroparesis drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

Major Driver Impacting Market Growth
The increasing prevalence of diabetes is expected to propel the growth of the gastroparesis drugs market going forward. Diabetes presents as a persistent health issue marked by high blood sugar levels stemming from inadequate insulin production or the body’s ineffective utilization of insulin. The increasing prevalence of diabetes is due to sedentary lifestyles, unhealthy dietary habits, genetic predisposition, urbanization, and aging populations, compounded by limited access to healthcare and rising obesity rates worldwide. Gastroparesis drugs are frequently prescribed for diabetic patients to alleviate symptoms such as nausea, vomiting, and delayed gastric emptying, common complications of diabetes affecting gastrointestinal motility. These medications aim to improve gastric function and enhance the quality of life for individuals with diabetes-related gastroparesis. For instance, in 2021, according to the International Diabetes Federation, a Belgium-based umbrella organization of over 240 national diabetes associations, the projected number of individuals living with diabetes is expected to increase to 643 million by 2030 and 783 million by 2045. Therefore, the increasing prevalence of diabetes is driving the growth of the gastroparesis drugs market.

Key Industry Players
Major companies operating in the gastroparesis drugs market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA., AstraZeneca plc, Abbott Laboratories, GSK plc, Takeda Pharmaceutical Inc., Teva Pharmaceutical Inc., Otsuka Pharmaceutical Co. Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Evoke Pharma Inc., Cadila Pharmaceuticals, Cipla Ltd., Neurogastrx Inc., Ipca Laboratories Ltd., ANI Pharmaceuticals Inc., Salix Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc, Rhythm Pharmaceuticals Inc., Processa Pharmaceuticals Inc., Aclipse Therapeutics LLC, ETX Pharma Inc.

The gastroparesis drugs market report table of contents includes:

1. Executive Summary
2. Gastroparesis Drugs Market Characteristics
3. Gastroparesis Drugs Market Trends And Strategies
4. Gastroparesis Drugs Market – Macro Economic Scenario
5. Global Gastroparesis Drugs Market Size and Growth
.
.
.
32. Global Gastroparesis Drugs Market Competitive Benchmarking
33. Global Gastroparesis Drugs Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Gastroparesis Drugs Market
35. Gastroparesis Drugs Market Future Outlook and Potential Analysis
36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model